Radioimmunotherapy-specificity
I have earlier stated that I opted for an experimental clinical study in which I received a radioimmunotherapy agent, Zevalin, as FIRST-LINE therapy for my follicular non-Hodgkin's lymphoma. First-line means that the patient has not received any prior treatment for the malignancy.
As a patient, I was most impressed with the logic of radioimmunotherapy. The agent is a protein antibody that SPECIFICALLY attacks the ymphoma cells, sparing normal tissues. Having received the radioimmunotherapy, I was fortunate to have only received 3 cycles of CHOP chemotherapy (considerably fewer than the number of CHOP cycles received by those patients receiving standard therapy).
I did not lose a single day of work from adverse effects of therapy. This fact, in my mind, is due to the specificity of the radioimmunotherapy.